Literature DB >> 12733477

Relative risks of reported serious injury and death associated with hemostasis devices by gender.

Dale R Tavris1, Beverly Gallauresi, Suzanne Rich, Carlos Bell.   

Abstract

PURPOSE: To assess relative risks by gender of reported serious injuries and deaths associated with the use of hemostasis devices, stratified by year of report, type of injury, and type of device.
METHODS: Reports from the Food and Drug Administration's Medical Device Reporting system and National Center for Health Statistics data on use of cardiac catheterization were used to estimate relative risks of reported serious injuries and deaths by gender.
RESULTS: Estimated risks of reported serious injuries and deaths associated with hemostasis devices were two to three times greater in females than in males for hemorrhage and hematoma (p < 0.0001), but there was no significant difference in risks by gender for infection.
CONCLUSIONS: Cardiac catheterization is sometimes associated with serious injuries and deaths. Among patients who receive hemostasis devices, the risk of these events are disproportionately greater in women.

Entities:  

Mesh:

Year:  2003        PMID: 12733477     DOI: 10.1002/pds.802

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  2 in total

1.  Enrollment and monitoring of women in post-approval studies for medical devices mandated by the Food and Drug Administration.

Authors:  Ellen Pinnow; Naomi Herz; Nilsa Loyo-Berrios; Michelle Tarver
Journal:  J Womens Health (Larchmt)       Date:  2014-01-09       Impact factor: 2.681

2.  The Food and Drug Administration Office of Women's Health: Impact of Science on Regulatory Policy: An Update.

Authors:  Merina Elahi; Noha Eshera; Nkosazana Bambata; Helen Barr; Beverly Lyn-Cook; Julie Beitz; Maria Rios; Deborah R Taylor; Marilyn Lightfoote; Nada Hanafi; Lowri DeJager; Paddy Wiesenfeld; Pamela E Scott; Emmanuel O Fadiran; Marsha B Henderson
Journal:  J Womens Health (Larchmt)       Date:  2016-02-12       Impact factor: 2.681

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.